Semi-mechanistic Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody, for Treatment of Solid Tumors Poster Semi-mechanistic Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody, for Treatment of Solid Tumors Abstract Trimer formation is key to the pharmacology of the bispecific ATG-101 but is difficult…Renee Fisher2024年9月16日
Blinatumomab Trimer Formation Poster Blinatumomab Trimer Formation Insights from a Mechanistic PKPD Model on the Implications for Switching from Infusion to Subcutaneous…Renee Fisher2024年9月16日
Dose Selection for DuoBody®-PD-L1x4-1BB (GEN1046) Poster Dose Selection for DuoBody®-PD-L1x4-1BB (GEN1046) Abstract DuoBody®-PD-L1x4-1BB (GEN1046) is an investigational, first-in-class, bispecific antibody designed to elicit an antitumor immune…Renee Fisher2024年9月9日
Optimizing Avidity of Bispecific Drugs Poster Optimizing Avidity of Bispecific Drugs Abstract Bispecific drugs have great potential to improve tissue selectivity through avid binding interactions but…Renee Fisher2024年9月9日
Effects of Tissue Targeting Bispecifics on Therapeutic Window Poster Effects of Tissue Targeting Bispecifics on Therapeutic Window Abstract Objectives: The presence of target receptors in non-target tissues can reduce the therapeutic window…Renee Fisher2024年9月9日
Optimizing Clinical Development: Saving Time and Costs Case Study 臨床開発の最適化:時間とコストを削減 Strategic Mechanisticモデリングソリューションは、免疫療法のバイオテクノロジー企業が新規治療法の臨床開発を加速させるのに役立ちます。Danielle Pillsbury2024年8月16日